Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 25 mg - patch, dermal - excipient ingredients: oleyl oleate; polyethylene; povidone; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - lacosamide 50 mg - film-coated tablet - 50 mg - lacosamide 50 mg - lacosamide

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius medical care australia pty ltd - 35986 - transfer set, continuous ambulatory peritoneal dialysis - a tubing set used in peritoneal dialysis for the treatment of chronic and acute renal failure in paediatric patients. it consists of tubing and connectors to peritoneal dialysis (pd) solution, drainage bag etc. the device is intended to be used in conjunction with peritoneal dialysis fluid by fresenius medical care.

Canada - English - myHealthbox

ecolab -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun seasons pty ltd - lactobacillus acidophilus, quantity: 0.75 billion cfu/g; lactobacillus rhamnosus, quantity: 3.5 billion cfu/g; fructooligosaccharides, quantity: 943.5 mg/g; lactobacillus salivarius ssp salicinius, quantity: 0.5 billion cfu/g; lactobacillus johnsonii, quantity: 0.25 billion cfu/g - powder, oral - excipient ingredients: - helps enhance/promote gastrointestinal system mucosa health ; maintain/support intestinal good/beneficial/friendly flora ; helps restore good/beneficial/friendly intestinal/gut/bowel flora ; nourish good/beneficial/friendly intestinal flora ; maintain/support gastrointestinal system health ; maintain/support gastrointestinal mucosal membrane health ; aids/assists repair of gastrointestinal/gut wall lining ; decrease/reduce/relieve abdominal bloating/distention ; decrease/reduce/relieve abdominal pain/discomfort ; relieve excessive belching ; helps decrease/reduce/relieve symptoms of mild gastritis ; decrease/reduce/relieve symptoms of heartburn ; helps decrease/reduce/relieve mild gastrointestinal tract inflammation ; decrease/reduce/relieve symptoms of stomach upsets

Canada - English - Health Canada

3m canada company - ethylene oxide - gas - 100% - ethylene oxide 100% - miscellaneous therapeutic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: povidone; oleyl oleate; polyethylene; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 15 mg - drug delivery system, transdermal - excipient ingredients: povidone; polyethylene; levulinic acid; oleyl oleate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: povidone; polyethylene; levulinic acid; oleyl oleate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.